Abstract 693P
Background
PD-1/PD-L1 monoclonal antibodies have revolutionised the landscape of cancer treatment. Nonetheless, some PD-L1+ patients do not respond to or become resistant to such therapy. The elevated expression of PD-L1 in tumours makes it an attractive target for ADC development, which could potentially alter the treatment for PD-1/PD-L1 inhibitor refractory/resistant (R/R) cancers.
Methods
HLX43 is a novel PD-L1-targeting ADC consisting of an engineered anti-PD-L1 humanised IgG1 antibody linked to a camptothecin-based toxin, with a drug to antibody ratio of 8. Our innovative linker-payload is activated preferentially in the tumour microenvironment, enabling its tumour-specific release of the toxin without needing internalisation of the ADC. Toxin release in PD-L1+ cancer cells is efficient and tumour-specific, minimizing damage to normal cells and reducing systemic toxicity from non-specific toxin release in periphery. HLX43 was examined in antigen binding, internalisation, and plasma stability assays; efficacy studies were performed in multiple CDX and PDX models.
Results
HLX43 has been shown to have similar affinity and internalisation rates as the parental antibody. It was stable in the plasma of rats and cynomolgus monkeys. In in vivo efficacy studies, HLX43 induced tumour regression in multiple PD-L+ CDX and PDX models, and was well tolerated across all dosing groups. Weekly administration of HLX43 8 mg/kg for three times significantly reduced tumours in the MDA-MB-231 model without causing weight loss. HLX43 exhibited superior anticancer efficacy compared to anti-PD-L1-GGFG-Dxd at equal doses in all models tested, including those with low PD-L1 levels, high heterogeneity, and non-responsiveness to PD-1/PD-L1 inhibitors. Preliminary toxicity assessments demonstrated good tolerability of HLX43 in rats and cynomolgus monkeys, with the maximum tolerated dose being 60 mg/kg in rats and 10 mg/kg in non-human primates. GLP toxicology studies will explore a higher dose at 20 mg/kg.
Conclusions
HLX43 showed promising efficacy and tolerability in preclinical assessments. It may offer a novel treatment for PD-1/PD-L1 inhibitor R/R cancers like NSCLC, HNSCC, ESCC, MEL, and OVC.
Clinical trial identification
Editorial acknowledgement
Shiqi Zhong of Shanghai Henlius Biotech, Inc.
Legal entity responsible for the study
Shanghai Henlius Biotech, Inc.
Funding
Shanghai Henlius Biotech, Inc.
Disclosure
Y. Shan, R. Liu, G. Song, H. Song, J. Jiang, C. Jia, Y. Chen, X. Yuan, Z. Hou, X. Wang, X. Hou, Y. Shen, C. Hu, H. Wei, Q. Wang, J. Zhu: Financial Interests, Personal, Full or part-time Employment: Shanghai Henlius Biotech, Inc.
Resources from the same session
678P - ExoDS: A bioengineered exosome-based capsule for targeted delivery of chemotherapy drugs to cancer cells and cancer stem cells
Presenter: Abhishek Dutta
Session: Poster session 17
679P - Lurbinectedin (LRB) pharmacokinetics (PK) and safety when co-administered with itraconazole (ITZ) in patients with advanced solid tumor
Presenter: Irene Moreno
Session: Poster session 17
680P - First results from the phase I trial of the ATR inhibitor, ART0380, in advanced solid tumors
Presenter: Kathleen Moore
Session: Poster session 17
681P - First-in-human study of ATR inhibitor IMP9064 monotherapy and in combination with PARP inhibitor senaparib in patients with advanced solid tumors
Presenter: Chia-Chi Lin
Session: Poster session 17
683P - Preclinical evaluation of HLX42, a novel EGFR-targeting ADC, for cetuximab or TKI resistant cancer
Presenter: Yongqiang Shan
Session: Poster session 17
684P - Phase I trial of SHR-A1811 in HER2-expressing advanced gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ) and colorectal cancer (CRC)
Presenter: Jin Li
Session: Poster session 17
685P - BL-M07D1, a HER2 antibody-drug conjugate in subjects with locally advanced or metastatic HER2 expressing breast cancer and other solid tumors
Presenter: Erwei Song
Session: Poster session 17
686P - Phase I study of HRS8807, an oral selective ER covalent antagonist (SERCA), in ER+/HER2- locally advanced (LA) or metastatic (M) breast cancer (BC)
Presenter: Jiong Wu
Session: Poster session 17
687P - A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER3 antibody) in patients with advanced HER3 positive solid tumours
Presenter: Johann de Bono
Session: Poster session 17
688P - Pharmacokinetics of HMBD-001, a human monoclonal antibody targeting HER3, a CRUK first-in-human phase I trial in patients with advanced solid tumours
Presenter: Oladipo Idowu
Session: Poster session 17